The osteocyte plays multiple roles in bone remodeling and mineral homeostasis

Medical Molecular Morphology

Volumn 48, Issue 2, 2015, Pages 61-68

  Chen, Huayue ^a   Senda, Takao ^a   Kubo, Kin ya ^b  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SEIJOH UNIVERSITY   (Japan)

Author keywords

FGF23; Lacunar canalicular system; Osteocyte; Osteoporosis; RANKL; Sclerostin

Indexed keywords

CASPASE INHIBITOR; DENTIN MATRIX PROTEIN 1; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MATRIX METALLOPROTEINASE 14; OSTEOPROTEGERIN; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCLEROSTIN; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN; MINERAL;

APOPTOSIS; ARTICLE; BONE REMODELING; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; GENE EXPRESSION; HOMEOSTASIS; HUMAN; MINERAL HOMEOSTASIS; NONHUMAN; OSSIFICATION; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BONE; BONE DEVELOPMENT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BONE AND BONES; BONE REMODELING; BONE RESORPTION; HOMEOSTASIS; HUMANS; MINERALS; OSTEOCYTES; OSTEOGENESIS;

EID: 84933673318     PISSN: 18601480     EISSN: 18601499     Source Type: Journal    
DOI: 10.1007/s00795-015-0099-y     Document Type: Article

References (75)

1. Chen H, Zhou X, Fujita H, Onozuka M, Kubo KY (2013) Age-related changes in trabecular and cortical bone microstructure. Int J Endocrinol 2013:1–9
2. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229–238
3. Dallas SL, Prideaux M, Bonewald LF (2013) The osteocyte: an endocrine cell … and more. Endocr Rev 34:658–690
4. Schaffler MB, Cheung WY, Majeska R, Kennedy O (2014) Osteocytes: master orchestrators of bone. Calcif Tissue Int 94:5–24
5. Dallas SL, Bonewald LF (2010) Dynamics of the transition from osteoblast to osteocyte. Ann N Y Acad Sci 1192:437–443
6. Turner CH, Robling AG, Duncan RL, Burr DB (2002) Do bone cells behave like a neuronal network? Calcif Tissue Int 70:435–442
7. Zhang K, Barragan-Adjemian C, Ye L, Kotha S, Dallas M, Lu Y, Zhao S, Harris M, Harris SE, Feng JQ, Bonewald LF (2006) E11/gp38 selective expression in osteocytes: regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol 26:4539–4552
8. Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, Wu W, Chrysovergis K, Yamada S, Birkedal-Hansen H, Poole AR (2005) The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci 118:147–156
9. Toyosawa S, Shintani S, Fujiwara T, Ooshima T, Sato A, Ijuhin N, Komori T (2001) Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res 16:2017–2026
10. Ubaidus S, Li M, Sultana S, de Freitas PH, Oda K, Maeda T, Takagi R, Amizuka N (2009) FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc 58:381–392
11. Komori T (2013) Functions of the osteocyte network in the regulation of bone mass. Cell Tissue Res 352:191–198
12. McNamara LM, Majeska RJ, Weinbaum S, Friedrich V, Schaffler MB (2009) Attachment of osteocyte cell processes to the bone matrix. Anat Rec 292:355–363
13. Han Y, Cowin SC, Schaffler MB, Weinbaum S (2004) Mechanotransduction and strain amplification in osteocyte cell processes. Proc Natl Acad Sci USA 101:16689–16694
14. Kamioka H, Honjo T, Takano-Yamamoto T (2001) A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone 28:145–149
15. Goodenough DA, Paul DL (2003) Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol 4:285–294
16. Lloyd SA, Loiselle AE, Zhang Y, Donahue HJ (2013) Connexin 43 deficiency desensitizes bone to the effects of mechanical unloading through modulation of both arms of bone remodeling. Bone 57:76–83
17. Ishihara Y, Kamioka H, Honjo T, Ueda H, Takano-Yamamoto T, Yamashiro T (2008) Hormonal, pH, and calcium regulation of connexin 43-mediated dye transfer in osteocytes in chick calvaria. J Bone Miner Res 23:350–360
18. Manolagas SC, Parfitt AM (2010) What old means to bone. Trends Endocrinol Metab 21:369–374
19. Tomkinson A, Reeve J, Shaw RW, Noble BS (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128–3135
20. Weinstein RS, Nicholas RW, Manolagas SC (2000) Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85:2907–2912
21. Chen H, Shoumura S, Emura S (2004) Ultrastructural changes in bones of the senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis. Histol Histopathol 19:677–685
22. Manolagas SC (2010) From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31:266–300
23. Furuzawa M, Chen H, Fujiwara S, Yamada K, Kubo KY (2014) Chewing ameliorates chronic mild stress-induced bone loss in senescence-accelerated mouse (SAMP8), a murine model of senile osteoporosis. Exp Gerontol 55:12–18
24. Ueda S, Ichiseki T, Yoshitomi Y, Yonekura H, Ueda Y, Kaneuji A, Matsumoto T (2014) Osteocytic cell necrosis is caused by a combination of glucocorticoid-induced Dickkopf-1 and hypoxia. Med Mol Morphol. doi:10.1007/s00795-014-0077-9
25. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464–475
26. Yang J, Shah R, Robling AG, Templeton E, Yang H, Tracey KJ, Bidwell JP (2008) HMGB1 is a bone-active cytokine. J Cell Physiol 214:730–739
27. Lacey DC, Simmons PJ, Graves SE, Hamilton JA (2009) Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage 17:735–742
28. Cerri PS, Boabaid F, Katchburian E (2003) Combined TUNEL and TRAP methods suggest that apoptotic bone cells are inside vacuoles of alveolar bone osteoclasts in young rats. J Periodontal Res 38:223–226
29. Verborgt O, Gibson GJ, Schaffler MB (2000) Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 15:60–67
30. Aguirre JI, Plotkin LI, Stewart SA, Weinstein RS, Parfitt AM, Manolagas SC, Bellido T (2006) Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 21:605–615
31. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB (2009) Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 24:597–605
32. Kennedy OD, Herman BC, Laudier DM, Majeska RJ, Sun HB, Schaffler MB (2012) Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone 50:1115–1122
33. Kobayashi Y, Udagawa N, Takahashi N (2009) Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr 19:61–72
34. Truswell AS (1958) Osteopetrosis with syndactyly; a morphological variant of Albers-Schönberg’s disease. J Bone Joint Surg Br 40:209–218
35. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543
36. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91–97
37. Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, Yao W, Lane NE, Harland RM, Loots GG (2012) Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci USA 109:14092–14097
38. Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T (2012) Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 50:209–217
39. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24:1651–1661
40. Kikuchi A, Yamamoto H, Sato A (2009) Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 19:119–129
41. Liu F, Kohlmeier S, Wang CY (2008) Wnt signaling and skeletal development. Cell Signal 20:999–1009
42. Rodda SJ, McMahon AP (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133:3231–3244
43. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S (2005) Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342–41351
44. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286:19489–19500
45. Moustafa A, Sugiyama T, Prasad J, Zaman G, Gross TS, Lanyon LE, Price JS (2012) Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int 23:1225–1234
46. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866–5875
47. Moriishi T, Fukuyama R, Ito M, Miyazaki T, Maeno T, Kawai Y, Komori H, Komori T (2012) Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading. PLoS ONE 7:e40143
48. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373–379
49. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997
50. Chen H, Senda T, Emura S, Kubo KY (2013) An update on the structure of the parathyroid gland. Open Anat J 5:1–9
51. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277–286
52. Genetos DC, Yellowley CE, Loots GG (2011) Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression. PLoS ONE 6:e17772
53. Findlay DM, Atkins GJ (2011) TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling. Adv Exp Med Biol 691:337–348
54. Wehmeyer C, Stratis A, Pap T, Dankbar B (2010) The role of the wnt inhibitor sclerostin in rheumatoid arthritis. Ann Rheum Dis 69:A21
55. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578–588
56. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK (2011) Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385–2395
57. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK (2009) A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 24:1662–1671
58. Ke H, Richards WG, Li X, Ominsky MS (2012) Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783
59. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754–766
60. Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W (2008) The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 82:445–453
61. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE (2008) Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485–3497
62. Yao GQ, Wu JJ, Troiano N, Insogna K (2011) Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 29:141–148
63. Gossiel F, Lane N, Eastell R (2011) The effect of glucocorticoid therapy on regulators of bone formation in postmenopausal women treated with teriparatide or alendronate. J Bone Miner Res 26(Suppl):S80
64. Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, Horan T, Steavenson S, Jacobsen F, Chen Q, Haldankar R, Lavallee J, Tipton B, Daris M, Sheng J, Lu HS, Daris K, Deshpande R, Valente EG, Salimi-Moosavi H, Kostenuik PJ, Li J, Liu M, Li C, Lacey DL, Simonet WS, Ke HZ, Babij P, Stolina M, Ominsky MS, Richards WG (2011) Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 26:2610–2621
65. Glantschnig H, Scott K, Hampton R, Wei N, McCracken P, Nantermet P, Zhao JZ, Vitelli S, Huang L, Haytko P, Lu P, Fisher JE, Sandhu P, Cook J, Williams D, Strohl W, Flores O, Kimmel D, Wang F, An Z (2011) A rate-limiting role for dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 338:568–578
66. Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494–498
67. Razzaque MS (2009) The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5:611–619
68. Hu MC, Shiizaki K, Kuro-o M, Moe OW (2013) Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75:503–533
69. ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348
70. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943–1946
71. Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008
72. Meir T, Durlacher K, Pan Z, Amir G, Richards WG, Silver J, Naveh-Many T (2014) PTH activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int 86:1106–1115
73. Ky B, Shults J, Keane MG, Sutton MS, Wolf M, Feldman HI, Reese PP, Anderson CA, Townsend RR, Deo R, Lo J, Gadegbeku C, Carlow D, Sulik MJ, Leonard MB (2013) FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circ Heart Fail 6:817–824
74. Miza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205:385–390
75. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408